Ginkgo Biloba Extract 761: Each participant will receive two 120mg Egb761 pills per day along the 6 month trial
Study summary
The goal of this clinical trial is to learn if the drug Egb761, produced from Ginkgo Biloba extract, works to improve the blood level of a biomarker of Alzheimer's disease, called phosphorylated-tau217 (p-tau217), which serves as a biomarker for disease activity in the brain. The main questions it aims to answer are:
Does drug Egb761 lower the plasma level of p-tau217 in patients with mild cognitive impairment? Does drug Egb761 improve cognitive and behavioral functions in these patients? Does Egb761 affect the blood levels of neurofilament-light (Nfl) and glial-fibrillary-acidic-protein (GFAP), which serve as additional biomarkers for brain disease activity?
Participants will:
Take Egb761 twice daily for 6 months Visit the clinic once every 3 months for checkups and tests Keep a diary of their symptoms
Eligibility
Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Mild cognitive impairment, as defined by MoCA score of 19-25.
* Preserved instrumental activities of daily life (iADL).
* Clinical impression of MCI of AD type, and lack of major medical and neurological conditions, as detailed in the exclusion criteria.
Exclusion Criteria:
* Extrapyramidal signs, existence of multi-infract dementia, or Fronto-Temporal dementia, according to clinical impression by treating cognitive Neurologist.
* Active cancer, severe cardio-pulmonary disease or other medical condition which negatively affects ability to evaluate patients and complete follow-up.
* Inability to sign an informed consent due to psychiatric or dementing condition.
* Hypersensitivity to any ingredient of the study medication.
Primary outcome measure(s)
Change in plasma phosphorylated-tau level — Plasma biomarker level tested at recruitment, at 3 and 6-months of trial Change in post-treatment plasma phosphorylated Tau level (6 months time point) as compared to pre-treatment level. P-tau level is reported in pg/ml
Trial sites (1)
Facility
City
Region
Status
Hadassah medical Center
Jerusalem
Israel
More Hadassah Medical Organization trials in Israel
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
